Phase III Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib E7080/MK-7902 in Combination with Pembrolizumab MK-3475 Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma LEAP-002

Brief Summary

Type:
Liver

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03713593

Study #:
STUDY00143740

Start Date:
Aug 04, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03713593

View Complete Trial Details & Eligibility at ClinicalTrials.gov